COSCIENS Biopharma Reports Q2 Loss of $2.7 Million, Revenue of $2.7 Million

COSCIENS Biopharma Inc. reported a Q2 loss of $2.7 million, or 85 cents per share, and revenue of $2.7 million. The Toronto-based drug developer's loss is attributed to ongoing research and development costs. The company continues to work on its pipeline of clinical-stage drug candidates.

COSCIENS Biopharma Inc. (CSCI), a Toronto-based biopharmaceutical company, announced its second quarter 2025 financial results, which reflected a net loss of $2.7 million, or 85 cents per share, and revenue of $2.7 million. The loss was primarily attributed to ongoing research and development (R&D) costs, which are a significant expense for the company as it works on its pipeline of clinical-stage drug candidates.

The company reported a 17% year-over-year increase in revenue, driven by strategic initiatives and operational improvements. However, the net loss widened due to the continued investment in R&D and a 27% workforce reduction. COSCIENS ended the quarter with $9.3 million in cash, providing a solid financial foundation for future growth.

The company also announced plans to voluntarily delist from the Nasdaq while maintaining its listing on the Toronto Stock Exchange (TSX). The delisting, expected around September 4, 2025, aims to reduce costs and streamline operations, with plans to transition to over-the-counter (OTC) trading in the US. This move is part of the company's broader strategy to focus on its core competencies and strengthen its financial position.

COSCIENS' pharmaceutical pipeline includes Macrilen, which missed primary endpoints in its Phase 3 DETECT trial, and AvenActive, currently in Phase 2a testing. The company's strategic initiatives also include plans to appoint a new CEO and reconstitute its board of directors, with the aim of enhancing corporate governance and creating shareholder value.

References:

[1] https://www.stocktitan.net/news/CSCI/